Requirements for Dispensing or Selling Chloroquine and Hydroxychloroquine in Ohio
As a result of the feedback received by the medical and patient community and at the request of Governor DeWine, the State of Ohio Board of Pharmacy has withdrawn proposed rule 4729:5-5-21 of the Administrative Code. Therefore, prohibitions on the prescribing of chloroquine and hydroxychloroquine in Ohio for the treatment of COVID-19 will not take effect at this time. This will allow the Board to reexamine the issue with the assistance of the State Medical Board of Ohio, clinical experts, and other stakeholders to determine appropriate next steps. Licensees should be aware that emergency rule 4729-5-30.2 is no longer effective and the requirements of that rule, including the inclusion of a diagnosis code on any prescription for chloroquine and hydroxychloroquine, are no longer applicable
鑒於來自醫護人員和相關患者的反饋 ，並應州長DeWine的要求，俄亥俄州醫藥協會特此撤回擬議條例4729：5-5-21 。由此，禁止在俄亥俄州開處方氯喹和羥氯喹用於治療COVID-19 的規定即日起失效。協會將在俄亥俄州醫學委員會，臨床專家及相關機構和人員的協助下重新審查該條例並確定適當的後續步驟。具醫療資質人員請注意，緊急條例4729-5-30.2不再有效，其規定在任何氯喹和羥基氯喹的處方上注明診斷代碼將不再適用。
4729:5-5-21 Prescription requirements for chloroquine and hydroxychloroquine.
(A) No prescription for chloroquine or hydroxychloroquine may be dispensed by a pharmacist or sold at retail by a licensed terminal distributor of dangerous drugs, including prescriptions for patients residing in Ohio dispensed or sold at retail by nonresident terminal distributors of dangerous drugs as defined in rule 4729:5-8-01 of the Administrative Code, unless the prescription bears a written diagnosis code from the prescriber or a statement indicating its veterinary medical purpose.
(B) Except as provided in paragraph (C) of this rule, prescriptions issued for chloroquine or hydroxychloroquine for prophylactic use related to COVID-19 or for the treatment of COVID-19 are strictly prohibited unless otherwise approved by the board’s executive director in consultation with the board president, at which time a resolution shall issue. Upon the effective date of this rule, all previous approvals for the use of chloroquine or hydroxychloroquine shall be deemed void and must be approved using the process outlined in this paragraph.
(C) The prohibition in paragraph (B) of this rule does not apply to prescriptions issued as part of a documented institutional review board-approved clinical trial to evaluate the safety and efficacy of the drugs to treat COVID-19. Prescriptions must include documentation that the patient is enrolled in a clinical trial.
(D) Paragraphs (B) and (C) of this rule shall also apply to medication orders and outpatient prescriptions dispensed by institutional pharmacies as defined in agency 4729 of the Administrative Code
Five Year Review (FYR) Dates: 07/30/2025
CERTIFIED ELECTRONICALLY Certification
Date Promulgated Under: 119.03
Statutory Authority: 4729.26, 3719.28
Rule Amplifies: 4729.26, 4729.54, 4729.55
Prior Effective Dates: 03/22/2020 (Emer.)